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The hippocampus in schizophrenia is characterized
by both hypermetabolism and reduced size. It
remains unknown whether these abnormalities are
mechanistically linked. Here we addressed this ques-
tion by using MRI tools that can map hippocampal
metabolism and structure in patients and mouse
models. In at-risk patients, hypermetabolism was
found to begin in CA1 and spread to the subiculum
after psychosis onset. CA1 hypermetabolism at base-
line predicted hippocampal atrophy, which occurred
during progression to psychosis, most prominently
in similar regions. Next, we used ketamine to model
conditionsofacutepsychosis inmice.Acuteketamine
reproduced a similar regional pattern of hypermetab-
olism,while repeatedexposure shifted the hippocam-
pus to a hypermetabolic basal state with concurrent
atrophy and pathology in parvalbumin-expressing
interneurons. Parallel in vivo experiments using the
glutamate-reducing drug LY379268 and direct mea-
surements of extracellular glutamate showed that
glutamate drives both neuroimaging abnormalities.
These findings show that hippocampal hypermetabo-
lism leads to atrophy in psychotic disorder and sug-
gest glutamate as a pathogenic driver.
INTRODUCTION
Previous research has demonstrated functional and structural
abnormalities in the hippocampus of patients with schizophrenia
and related psychotic disorders. Among the most prominent arehypermetabolism and volume reduction of the hippocampus as
reflected in neuroimaging studies (Heckers et al., 1998; Kawa-
saki et al., 1992; Malaspina et al., 2004; Medoff et al., 2001; Mo-
lina et al., 2003; Steen et al., 2006).
The hippocampal formation is a complex structure comprised
of different subregions extending along the posterior-to-anterior
extent of the medial temporal lobe to form a neural circuit (Small
et al., 2011). Recent neuroimaging studies have shown that the
CA1 and subiculum in the anterior body of the hippocampus
are differentially affected in schizophrenia, as reflected by vol-
ume (Ku¨hn et al., 2012), shape (Csernansky et al., 1998; Narr
et al., 2004), and metabolic measures (Schobel et al., 2009b).
The overlap between the anatomical pattern of hippocampal hy-
permetabolism and apparent atrophy suggests that these neuro-
imaging abnormalities might share a common pathophysiologic
mechanism. However, as these neuroimaging tools have not yet
been applied within the same population of subjects the precise
concordance between hypermetabolism and atrophy remains
unknown. Furthermore, as it is now understood that schizo-
phrenia is a progressive brain disease (Andreasen et al., 2011),
the temporal sequence of these pathologic features remains
uncharted.
Accordingly, to map the spatial and temporal pattern of hippo-
campal metabolism and structure, we longitudinally assessed
subjects who fulfilled ‘‘clinical high-risk’’ criteria using magnetic
resonance imaging (MRI) methods. Previous studies have shown
that about 30%of this enriched group of subjects with prodromal
symptoms progress to psychosis (Fusar-Poli et al., 2012). We
previously reported that baseline MRI maps of cerebral blood
volume (CBV), an established hemodynamic correlate of basal
metabolism (Gonza´lez et al., 1995; Raichle, 1983), predicts pro-
gression to psychosis (Schobel et al., 2009b). In the present
study, we imaged subjects at baseline and after follow-up
periods, using both CBV-fMRI and structural MRI measures.
The results show that hippocampal hypermetabolism antedatesNeuron 78, 81–93, April 10, 2013 ª2013 Elsevier Inc. 81
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Imaging Hippocampal Dysfunction in Schizophreniaatrophy and that over time an anatomical concordance emerges
between the specific pattern of hypermetabolism and atrophy.
The anatomical concordance of metabolism and structure
suggested a common mechanism, and based upon current glu-
tamatergic theories (Lisman et al., 2008; Moghaddam and Javitt,
2012) we hypothesized that elevations in extracellular glutamate
might act as a pathogenic driver. This hypothesis was informed,
in part, by prior observations in a mouse model developed to
understand how a deficiency in glutamate release relates to
schizophrenia-relevant neuroimaging and behavioral pheno-
types (Gaisler-Salomon et al., 2009). By fMRI, reductions in
CBV were observed in the same subregions characterized by
hypermetabolism in schizophrenia; moreover this ‘inverse’
neuroimaging phenotype was accompanied by behavioral
and neurochemical phenotypes that were in all cases the inverse
of what typically characterizes animal models of schizophrenia.
These results were interpreted in the context of a growing
number of studies suggesting that excess extracellular
glutamate may be a contributing factor in psychosis. Systemic
administration of N-methyl-D-aspartate (NMDA) receptor antag-
onists also provides proof of this principal. These agents induce
both positive and negative symptoms of the disease in healthy
volunteers (Krystal et al., 1994) and exacerbate psychotic symp-
toms and cognitive impairments in patients with schizophrenia
(Malhotra et al., 1997). Moreover, in experimental animals,
NMDA antagonists elevate extracellular glutamate (Moghaddam
and Javitt, 2012) and induce hypermetabolism in cerebral cortex
as detected by CBV-fMRI (Gozzi et al., 2008) at doses that
induce behavioral and neurochemical abnormalities homolo-
gous with schizophrenia (Bickel and Javitt, 2009; Jentsch and
Roth, 1999; Moghaddam et al., 1997; Mouri et al., 2007; Pinault,
2008).
To test the hypothesis that excess glutamate drives hippo-
campal subregional hypermetabolism and atrophy in psychosis,
we used administration of the NMDA antagonist ketamine in
mice, where invasive technologies can be deployed to precisely
map extracellular glutamate within the hippocampal circuit. First,
we used the same MRI tools applied to human patients to show
that that ketamine administration in rodents replicated the spe-
cific anatomical pattern of hippocampal dysfunction in schizo-
phrenia. We then conducted a series of experiments utilizing
an in vivo glutamate biosensor method (Hu et al., 1994) in multi-
ple hippocampal subregions to show that ketamine causes a
regionally preferential increase in extracellular glutamate, and
that a glutamate-reducing agent ameliorates this increase as
well as MRI-detected hippocampal hypermetabolism and atro-
phy. Finally, we performed postmortem analyses to determine
histopathological correlates of the neuroimaging phenotypes.
RESULTS
Mapping a Neuroimaging Pattern of Hippocampal
Dysfunction during the Emergence of Psychosis
Twenty-five subjects at clinical high-risk for a psychotic disorder
were imaged while experiencing prodromal symptoms, and then
20 were reimaged at clinical follow-up totaling 80% of the orig-
inal sample. One patient in the progressor group, and four
patients in the nonprogressor group were lost to brain imaging82 Neuron 78, 81–93, April 10, 2013 ª2013 Elsevier Inc.follow-up, although none were lost to clinical follow-up. The
average follow-up period and interscan interval was 2.4 years.
During this time, 10 of the 25 subjects progressed to psychosis,
and 15 subjects did not develop a psychotic disorder (see Tables
S1 and S2 available online). Subjects were comparable on base-
line demographic variables including age (t23 = 0.7, p = 0.48), sex
(Fisher’s exact p = 1.0), years education (t22 = 0, p = 1) and
follow-up interval (t18 = 0.8, p = 0.76).
Mapping Hippocampal CBV
Subjects were imaged at baseline and at follow-up using the
steady-state gadolinium-enhanced fMRI technique, as previ-
ously described (Moreno et al., 2007). Based on our previous
findings (Schobel et al., 2009b) we focused on the anterior
aspect of the hippocampal formation. For each subject, mean
CBV was measured from the following hippocampal subre-
gions—entorhinal cortex (EC), dentate gyrus (DG), CA3, CA1,
and subiculum (SUB). A repeated-measures analysis of variance
with subregion (EC, DG, CA3, CA1, and SUB) and side (left, right)
aswithin-subject factors and outcome (progression to psychosis
versus non-progression) as between-subjects factor revealed a
subregion by progression to psychosis interaction (F4,18 = 3.1,
p = 0.04); Post hoc t tests revealed increases in CA1 subfield
CBV averaged across sides (t23 = 2.7, p = 0.01), and, in par-
ticular, increases in left-sided CA1 subfield CBV (t23 = 3.5,
p = 0.002).
To test for longitudinal changes in CBV from baseline to
follow-up, a repeated-measures analysis with time (baseline
and follow-up) and subregion (EC, DG, CA3, CA1, and SUB) as
within-subjects factors and progression status (psychosis
versus not) as a between-subjects factor was used. The multi-
variate component of the analysis identified a significant subre-
gion by time by group interaction (F4, 13 = 3.5, p = 0.04). Post hoc
t tests revealed this interaction to be driven by CBV increases in
subiculum from baseline to follow-up bilaterally in the progressor
group (t18 = 3.7, p = 0.002); increases in CA1 CBV did not change
significantly from time 1 to time 2, remaining relatively higher in
the progressor group at both baseline (t23 = 2.7, p = 0.01) and
follow-up (t18 = 3.1, p = 0.006). EC, DG, and CA3 were not signif-
icantly different between groups at baseline or follow-up. Anti-
psychotic or antidepressant drug exposure had no effect on
CBV values in this analysis (Figure 1A).
To confirm that hippocampal hypermetabolism is predictive of
psychosis, we entered hippocampal left anterior CA1 CBV into a
Cox regression model, controlling for demographics and follow-
up interval, with time to psychosis as the dependent variable.
Left anterior CA1 CBV powerfully predicted time to psychosis
in the Cox model (Wald (t1) = 8.5, p = 0.003). We further explored
whether brain metabolism or symptoms were more powerful
predictors of outcome. Similar to other larger prodromal cohort
studies (Cannon et al., 2008), unusual thought content (Wald(t1) =
2.9, p = 0.09) suspiciousness, (Wald(t1) = 2.9, p = 0.08) and con-
ceptual disorganization (Wald(t1) = 3.5, p = 0.06) also predicted
time to psychosis at a trend level when entered separately into
this model. When behavioral variables were entered together
into the model with left anterior CA1 CBV, brain metabolism
maintained its predictive strength (Wald(t1) = 8.8, p = 0.003),
whereas behavioral measures were no longer predictive of clin-
ical outcome (all p’s > 0.33), suggesting that left CA1 CBV is a
Figure 1. Mapping a Spatiotemporal Pattern of Hippocampal Hypermetabolism and Atrophy during the Emergence of Psychosis
(A) Tracking changes in hippocampal cerebral blood volume (%CBV) over time in high-risk subjects who progress to psychosis versus those who do not (‘‘no
psychosis’’) shows that CA1%CBV (upper graph) is increased in progressors at the prepsychotic baseline stage (‘‘Time 1’’) and remains elevated at the onset of
psychosis (‘‘Time 2’’). In the subiculum (SUB) (lower graph), no%CBV differences were observed at baseline (‘‘Time 1’’), but an abnormal increase emerged after
the onset of psychosis (‘‘Time 2’’).
(B) No changes in whole hippocampal volume between the progressors (‘‘psychosis’’) and nonprogressors (‘‘no-psychosis’’) were observed in the prepsychotic
baseline stage (‘‘Time 1’’), but atrophy was observed after the onset of psychosis (‘‘Time 2’’).
(C) Changes in hippocampal morphometric shape over time between the progressors and non-progressors pinpoints the site of dominant hippocampal volume
loss. The right and left hippocampal bodies are shown over the posterior-to-anterior long axis, with warmer colors indicating sites of statistically significant
morphometric shape change between the groups over time. A gradient of statistical significance over the long axis is observed, with greatest changes observed in
the anterior hippocampal body, in particular in the left CA1 and subiculum.
(D) A vector map shows the directionality of morphometric changes between the groups. Arrows pointing inward along the surface of the hippocampal shape
indicate negative hippocampal shape change in progressors to psychosis versus non progressors, with the greatest effects observed bilaterally in the anterior
CA1 and subiculum. Arrows that run parallel to the long axis, as shown in the anterior uncus and posterior body indicate a shift in three dimensions of the
hippocampal body potentially consistent with either shrinkage or movement of the entire structure in space over time between the groups.
See also Tables S1 and S2.
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chosis than subthreshold psychotic symptoms.
Mapping Hippocampal Structure
In the same subjects, MRI was used to map hippocampal struc-
ture and generate measures of hippocampal volume and hippo-
campal shape as previously described (Schobel et al., 2009a;
Styner et al., 2003, 2007). At the initial assessment, to test
for baseline differences in hippocampal volume, a repeated-
measures analysis of variance with side (left, right) as within-
subject factors and outcome (progression to psychosis versus
nonprogression) as between-subjects factor revealed no main
effect of progression status (F1,22 = 0.96, p = 0.36) and no
side-by-conversion interaction (F1,22 = 1.1, p = 0.30). To testfor hippocampal atrophy over time, a repeated-measures anal-
ysis with time (baseline and follow-up) and hippocampal volume
as within-subjects factors and progression status (psychosis
versus not) as a between-subjects factor, controlling for baseline
hippocampal volume, revealed a group by time interaction
(F1,16 = 17.6, p = 0.001), in which the hippocampal volume of
progressors to psychosis declined bilaterally (t18 = 4.6, p <
0.001; Figure 1B). Antipsychotic or antidepressant exposure
had no effect on hippocampal volumes at either time 1 or time
2 between groups.
To map the site of within the hippocampus where atrophy
where occurred and whether it was localized to a specific hippo-
campal subregion, morphological analysis of the longitudinalNeuron 78, 81–93, April 10, 2013 ª2013 Elsevier Inc. 83
Figure 2. Overlap of Anatomical Patterns of Psychosis-Related Hypermetabolism and Atrophy
(A) Magnified view of Figure 1C, showing the statistical significance p value map of longitudinal left hippocampal body CA1 subfield morphometric shape change
between progressors and nonprogressors to psychosis. The orientation fromposterior (top) to anterior is divided into representativeMRI slices along the long axis
of the hippocampal body as indicated by horizontal dotted lines corresponding with frames in (B).
(B) Color map of %CBV shown for a single participant acquired at baseline 24 months prior to onset of psychotic symptoms. Illustrated are 3 mm slices in the
hippocampus body from posterior to anterior of the left CA1 subfield; each frame corresponding with levels demarcated by dotted lines in Panel A. The map
shows a gradient in this individual in left CA1, with %CBV progressively higher (warmer colors) in anterior sectors.
(C) Group-wise data of left anterior CA1%CBV at baseline, showing differences between patients that subsequently progressed to psychosis (progressors;
(‘‘yes,’’ white bars) versus nonprogressors (‘‘no,’’ black bars). Each bar graph corresponds with the posterior-anterior levels demarcated in (A) and (B). **p < 0.01
peak difference in rCBV in progressors relative to nonprogressors. Data are represented as mean ± SEM.
(D) The association between baseline left anterior CA1%CBV and hippocampal (HIPP) volume change. The scatter plots show data averaged from slices 1–6
shown in (A)–(C) into two posterior, middle, and anterior slices. There is a negative association between CA1%CBV and longitudinal hippocampal volume change
that becomes progressively stronger across the posterior-anterior axis reaching significance only in the left anterior CA1 (bottom scatter plot; black = non
progressors, white = progressors to psychosis). n = 19 of the total n = 25 cases are represented in the scatter plot, with n = 5 lost to brain imaging follow-up, and
one case excluded due to MRI artifact preventing calculation of hippocampal CBV throughout the long axis.
See also Tables S1 and S2.
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to nonprogressors, progressors had volume loss localized
to the CA1 and subiculum subregions, which were most promi-
nent in the anterior body of the left hippocampus (Figures 1C
and 1D).
The Relationship between Hippocampal CBV and
Atrophy
To investigate the spatiotemporal relationship between hippo-
campal CBV acquired at baseline and subsequent hippocampal
structural changes, we first visualized the left hippocampal
morphometric shape result (Figure 1C) in a magnified fashion,
focusing upon the extent of the long axis of the hippocampal84 Neuron 78, 81–93, April 10, 2013 ª2013 Elsevier Inc.body containing the left CA1 subfield (Figure 2A). We then gener-
ated baseline CA1 CBV values in subjects along the extent of the
same area of the long axis of the hippocampal body. CBV values
from the posterior to anterior extent of the hippocampal body
were entered into a single multivariate analysis of variance with
hippocampal long axis CBV as within-subjects factors and pro-
gression status (psychosis versus not) as a between-subjects
factor, controlling for demographics (both left and right sides
included in the analysis; Figure 2B shows an example of left
long axis CA1 CBV of the hippocampal body from posterior to
anterior in an individual subject). CBV increases at baseline
were localized to the two most anterior slices of the left body
Figure 3. Acute Ketamine Administration
in Mice Recapitulates the Psychosis-Asso-
ciated Pattern of Hippocampal Hyperme-
tabolism
Changes in hippocampal relative CBV (rCBV; see
Experimental Procedures for calculation) in anes-
thetized mice following acute administration of
ketamine (30 mg/kg) are shown. Compared to
saline (black lines), ketamine (red lines) evoked
significant increases in CA1 (A) and subiculum
rCBV (B), significant at 16 min postinjection. The
EC (C), CA3 (D), and DG (E) showed nonsignificant
increases relative to saline. *p < 0.05 peak differ-
ence in rCBV, relative to saline. Data are repre-
sented as mean ± SEM.
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respectively; Figure 2C). Taken together, the results show an
anatomical overlap between left anterior hippocampal body
CA1 CBV acquired at baseline and the most significant mor-
phologic shape change across the transition to psychosis found
in left anterior hippocampal body CA1. To confirm this spatio-
temporal relationship, we tested the association of baseline
hippocampal CBV along the long axis to subsequent hippocam-
pal volume change. Higher baseline CBV values in left CA1 in
the anterior hippocampal body predicted subsequent hippo-
campal atrophy at follow-up (beta = 0.63, t = 2.53, p = 0.03),
an association not found in the posterior body (beta = 0.17,
t = 0.76, p = 0.45) and midbody CA1 subfields (beta = 0.3,
t = 1.2, p = 0.24; Figure 2D). Moreover, this association was
specifically found between elevated baseline left anterior CBV
values and subsequent left hippocampal volume decrease
(beta = 0.58, t = 2.9, p = 0.01).
Mapping a Neuroimaging Pattern of Hippocampal
Dysfunction Induced by Acute Ketamine Administration
in Mice
Male C57B6 mice aged 50–70 days postnatal (n = 9 per group),
an age range analogous to young adulthood in the human
(Laviola et al., 2003), were used for this experiment. While the
mice were stably anesthetized, we administered an acute keta-
mine (30 mg/kg) or saline challenge; CBV was then measured
within subregions (EC, DG, CA3, CA1, SUB) of the ventral hippo-
campal body at 16, 32, and 48 min postchallenge using previ-
ously described CBV-fMRI imaging methods (Moreno et al.,
2006). A mixed ANOVA showed an interaction between drug
challenge and postinjection time, with ketamine-induced in-
creases in CBV observed in CA1 (F4,13 = 4.1, p = 0.02; Figure 3A)
and subiculum (F4,13 = 3.8, p = 0.03) subregions (Figure 3B).
Planned pairwise comparisons showed significant increases
(relative to preinjection baseline) at 16 min (CA1: t8 = 4.3, p =
0.003; SUB: t8 = 4.8, p = 0.001) which persisted at a trend
level at 32 min (CA1: t8 = 1.9, p = 0.09; SUB t8 = 2.1, p = 0.07;Neuron 78, 81Figures 3A and 3B) For both CA1 and
subiculum, saline injection produced no
significant increases in CBV relative to
pre-injection baseline. Moreover, there
were no statistically significant effects ofketamine (relative to baseline or saline) within EC, DG, or CA3
(Figures 3C–3E).
Mapping a Neuroimaging Pattern of Hippocampal
Dysfunction after Repeated Ketamine Administration in
Mice
Mapping Hippocampal CBV
To model episodic neurochemical conditions that may precipi-
tate psychosis, we exposed C57B6 male mice ages 35–
45 days (n = 6–10 per group), to three times weekly exposure
to ketamine (8 mg/kg, 16 mg/kg, and 32 mg/kg dose groups)
or saline for one month (total 12 doses per group) (Figure S1).
The age range is considered to be analogous to the period
from midadolescence through young adulthood in human (Lav-
iola et al., 2003), during which time the risk for psychosis rises
sharply in males (Paus et al., 2008). At the end of the 1 month
treatment (at age 65–75 days), following a 48 to 72 hr washout
period, we imaged basal CBV. An ANOVA revealed a main effect
of drug dose on basal hippocampal CBV at 1 month (F3,28 = 3.3,
p = 0.035); planned pairwise comparisons of each ketamine
dose group to saline showed that repeated ketamine led, with
an inverse ‘‘U’’ shaped dose function, to an increase in basal-
state CBV preferentially in the CA1 subfield (Figure 4A). Specif-
ically, relative to saline administration, exposure to intermittent
ketamine 8 mg/kg resulted in increases in basal CBV in the
CA1 subfield (t3 = 4.3, p = 0.02); exposure to the 16/mg dose
resulted in increases in the CA1 subfield (t9 = 2.3, p = 0.05) as
well as trends for increases in the CA3 subfield (t9 = 1.8, p =
0.08) and subiculum (t9 = 1.9, p = 0.09). Exposure to the
32 mg/kg dose resulted in less robust increases in basal CBV
across subregions (all p’s > 0.2).
Mapping Hippocampal Structure
Structural imaging was performed on the same mice used in the
repeated ketamine study at baseline (at age 35–45 days, n = 6–
10 per group) and following the 1 month treatment (at age 65–
75 days). For this study, for total forebrain and total hippocampal
volumewere determined using structural T2-weighted horizontal–93, April 10, 2013 ª2013 Elsevier Inc. 85
Figure 4. Repeated Ketamine Administra-
tion Recapitulates the Psychosis-Associ-
ated Pattern of Hippocampal Hypermetabo-
lism and Atrophy
(A) Repeated intermittent ketamine administration
over 1month (8mg/kg, 16mg/kg, 32mg/kg versus
saline) led to a metabolic state change in hippo-
campal rCBV: it dose dependently led to increases
in basal rCBV measured at 48 hr after washout of
the drug. Statistically significant increases were
observed for the 8 and 16 mg/kg repeated treat-
ments. *p < 0.05 relative to saline treatment. Data
are represented as mean ± SEM.
(B) Compared to saline control, negative hippo-
campal volume change was found in mice receiv-
ing higher doses of repeated ketamine adminis-
tration, with the effect asymptoting at 16 mg/kg.
**p < 0.01; ***p < 0.001, relative to saline treatment.
(C) Rostral view of morphometric shape change
map. Compared to saline control, areas of nega-
tive hippocampal volume change were localized in
the 16 mg/kg group to the left ventral aspects of
hippocampal body by morphometric shape anal-
ysis; areas of statistically significant volume loss
are shown by orange clusters.
(D) Average cross-sectional hippocampal area (mm2) as measured in fixed tissue from a subset of mice shown in (A)–(C). Relative to the saline group saline (dark
bars), mice receiving repeated ketamine 16 mg/kg (light gray stippled bars) for 1 month showed areal reductions in the caudoventral aspect of the hippocampus
(see main text for anatomical boundaries). *p < 0.05 relative to saline. Data are represented as mean ± SEM.
See also Figure S1.
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tion, 500 mM slice thickness). Not surprisingly, during acute
exposure there was no change in hippocampal volume (F3,26 =
0.64, p = 0.59). We next compared hippocampal volume change
over the onemonth among the four groups, controlling for whole-
brain volume. Results revealed a main effect of drug treatment
on hippocampal volume change (F3,26 = 12.9, p < 0.001). Post
hoc tests showed the 16 mg/kg (t18 = 5.3, p < 0.001) and
32 mg/kg (t14 = 3.8, p = 0.002) groups had a relative loss of vol-
ume; specifically, mice treated at these doses showed no growth
or a loss of hippocampal volume over one month relative to the
saline-exposed group, which showed increases in volume over
the month (Figure 4B). To map the site of negative hippocampal
growth, morphological analysis of the longitudinal assessments
was performed. Compared to the saline group, mice exposed to
16mg/kg had volume loss localized to the ventral portion of
hippocampal body (Figure 4C).
Gross hippocampal structure was also assessed post-mor-
tem in fixed, immunostained tissue in a subset of mice from
this study and the related experiment assessing the effect of
cotreatment with LY379268 (see below). For these studies, we
systematically sampled coronal sections through the body of
the hippocampus, calculating average cross-sectional area of
blocks matched across groups for location within hippocampus.
Guided by the imaging findings, we divided the body into a
rostrodorsal portion (1.0 to 2.4 mm posterior to Bregma; rostral
to the emergence of the ventral hippocampus) and caudo-
ventral portion (2.5 to 4.0 mm posterior to Bregma, including
ventral hippocampus). An omnibus analysis including the three
repeated drug treatment groups (saline-only control, saline co-
treatment with ketamine [16 mg/kg], and LY379268 [10 mg/kg]86 Neuron 78, 81–93, April 10, 2013 ª2013 Elsevier Inc.co-treatment with ketamine [16 mg/kg]) showed a significant
interaction between drug condition and position within the
hippocampus (F2,14 = 4.7, p < 0.05). Planned comparisons
between the saline control and repeated ketamine groups
revealed that while there was no difference between drug groups
for the rostrodorsal hippocampus (t8 = 0.26, one-tailed p > 0.4),
the caudoventral hippocampus was reduced in size in the
repeated ketamine-exposed mice relative to saline (t8 = 1.93,
p < 0.05) (Figure 4D).
Excess Glutamate Mediates the Psychosis-Associated
Neuroimaging Pattern of Hippocampal Dysfunction
To determine whether extracellular glutamate mediated the
acute effect of ketamine on hippocampal CBV, ketamine
30 mg/kg or saline was administered via an i.p. catheter under
the same experimental conditions used in the acute ketamine
CBV experiments above, and the extracellular glutamate
response was recorded in specific hippocampal subregions
in vivo following implantation of an amperometric glutamate
biosensor (Hu et al., 1994). An ANOVA showed a significant
ketamine-evoked increase in hippocampal glutamate (F3,24 =
4.6, p = 0.01); planned comparisons showed increases in the
CA1 (t11 = 2.4, p = 0.03) and SUB (t10 = 2.5, p = 0.03) relative
to the EC which showed no increase following ketamine (Figures
5A and 5B).
To determine whether increases in extracellular glutamate
were necessary for ketamine-evoked hippocampal hyper-
metabolism to occur, we pretreated mice with LY379268
(10 mg/kg), a drug that reduces neuronal glutamate release
through activation of presynaptic mGlur2/3 receptors (Lorrain
et al., 2003; Monn et al., 1999). Mice were pretreated for
Figure 5. Glutamate Mediates the Psycho-
sis-Associated Pattern of Hippocampal
Hypermetabolism Induced by Acute Keta-
mine Administration
(A) As shown by in vivo recording of extracellular
glutamate efflux performed under the same con-
ditions as for the imaging shown in Figure 3, acute
ketamine administration (30 mg/kg) resulted in
increases in evoked extracellular glutamate in CA1
and subiculum (SUB) and not in entorhinal cortex
(EC) or dentate gyrus (DG). *p < 0.05 relative to EC.
(B) The time course of the effect of acute ketamine
administration in the CA1 (red line) versus ento-
rhinal cortex (EC; black line).
(C) Pretreatment with the mGluR2/3 agonist
LY379268 (10mg/kg) blocked the evoked
extracellular glutamate response within the CA1
subfield.
(D) Relative to saline pretreatment, pretreatment
with mGluR2/3 agonist LY379268 (10 mg/kg)
blocked the evoked rCBV response, with a trend
for also reducing basal rCBV as measured at
‘‘Time 0’’ (prior to the ketamine challenge).
Data for (A)–(D) are represented as mean ± SEM.
See also Figure S2.
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cellular glutamate response or CBV response to acute keta-
mine challenge 30 mg/kg. An ANOVA revealed that L379268
blocked the ketamine-evoked glutamate elevation in CA1/
SUB (F1,11 = 5.5, p = 0.04; Figure 5C). At this glutamate-sup-
pressing dose, LY379268 also prevented ketamine-induced
increases in CA1/SUB CBV (overall F2,27 = 21.7, p < 0.001);
planned comparisons of LY379268 to SAL pretreatment (p <
0.001; Figure 5D).
To determine whether glutamate mediated the induction of
the hypermetabolic state and relative volume loss observed
with repeated intermittent ketamine exposure, mice were
administered either saline or LY379268 (10 mg/kg) 1 hr prior
to receiving each ketamine (16 mg/kg) treatment, totaling 12
(3 weekly) cotreatments over 1 month. Prior to endpoint CBV
and structural hippocampal imaging, all animals were withdrawn
from treatment for 48 hr. LY739268 prevented ketamine-
induced basal increases in CBV throughout the trisynaptic
circuit and subiculum (DG F1,17 = 7.0, p = 0.01; CA3 F1,17 =
5.2, p = 0.04; CA1 F1,17 = 4.3, p = 0.05; SUB F1,17 = 6.1, p =
0.03; Figure 6A). At this basal hypermetabolism-suppressing
dose, LY379268 also prevented the repeated ketamine-induced
hippocampal volume decrease over the 1 month exposure
(F1,17 = 11.7, p = 0.003; Figure 6B). Additional morphometric
analyses revealed that the region showing the most consistent
relative protection overlapped with mid-body CA1 and subicu-
lum (Figure 6C). This was consistent with the post-mortem anal-
ysis (performed as described above) which showed an effect of
LY379268 cotreatment on hippocampal structure following
repeated ketamine (Figure 6D). Specifically, while there were
no group differences observed in the rostrodorsal hippocam-
pus, the size of the caudoventral hippocampus was larger in
repeated ketamine-treated mice receiving LY379268 co-treat-
ment than mice co-treated with saline (t12 = 2.1, one-tailed
p < 0.05).GABAergic Interneuronal Markers Are Linked to the
Neuroimaging Pattern of Hippocampal Dysfunction
To further investigate circuit mediators of the above effects
of repeated ketamine, we quantified the density of the par-
valbumin-positive (PV+) subpopulation of GABAergic interneu-
rons in the CA fields of three groups from the longitudinal
treatment studies (saline/saline [saline control], saline/ketamine
16 mg/kg, LY379268 10 mg/kg/ketamine 16 mg/kg). A general
linear model showed significant differences in PV+ cell density
across treatment groups (Wald chi-square [df = 2] = 8.1, p <
0.05). Pairwise comparisons (Wald) revealed that repeated keta-
mine exposure (saline/ketamine 16 mg/kg group) led to signifi-
cant decreases in PV+ cell density relative to the saline control
group (p < 0.01; Figure 7A). PV+ cell density in the LY379268
was intermediate, not differing significantly from either saline
control or the saline/ketamine group (Figure 7A). Interestingly,
there was a strong trend across the three groups for decreases
in PV+ cell density (relative to the mean saline control value) to
correlate with increases in basal CA1 CBV observed after
repeated ketamine exposure (r = 0.49, p = 0.06; Figure 7B). In
turn, this abnormal increase in basal CA1 CBV was significantly
related to hippocampal volume loss (r = 0.57, p = 0.006;
Figure 7C).
DISCUSSION
Schizophrenia characteristically has a gradual onset beginning
with a prodromal stage and culminating with psychotic symp-
toms. Neuroimaging studies have demonstrated pathological
involvement of the hippocampal formation in schizophrenia
with structural and functional imaging techniques. These find-
ings pose questions about the fundamental relationship between
hippocampal metabolism and structure during the onset and
course of schizophrenia. Our longitudinal study of prodromal
patients revealed a spatiotemporal pattern of hippocampalNeuron 78, 81–93, April 10, 2013 ª2013 Elsevier Inc. 87
Figure 6. Hippocampal Hypermetabolism
and Volume Loss Induced by Repeated
Ketamine Administration Is Ameliorated by
a Glutamate Release Inhibitor
(A) rCBV following repeated treatment over one
month with ketamine and cotreatment with either
saline (red bars) or LY379268 10 mg/kg (blue
bars). Cotreatment with LY379268 ameliorated the
repeated ketamine-induced increase in basal
hippocampal rCBV, as evident from comparison
with saline pretreatment. The saline/ketamine
group is the same as that previously shown in
Figure 4. *p < 0.05 relative to saline.
(B) LY379268 (10 mg/kg) cotreatment during
repeated ketamine exposure (blue bars) amelio-
rated the hippocampal (HIPP) volume loss, as
evidenced by significantly preserved (larger) HIPP
volume in the LY379268 (blue symbols) relative
to the saline co-treatment group (red symbols).
**p < 0.01 relative to saline/ketamine.
(C) Rostral view of morphometric shape
change map. Pretreatment with LY379268
resulted in protection in the CA fields of the
hippocampal body as measured by MRI-based
morphometric analysis; areas of statistically sig-
nificant volume protection are shown by orange
clusters.
(D) Average cross-sectional hippocampal area (mm2) in fixed brains of mice represented in (A)–(C). Volume protection of LY379268 pre-treatment is most evident
in the caudoventral aspect of the hippocampus (see main text for anatomical boundaries).
*p < 0.05 relative to saline cotreatment; for all groups, the saline/ketamine group is the same as that represented in Figure 5.
Data for (A), (B), and (D) are represented as mean ± SEM.
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symptoms to psychosis. During prodromal prepsychotic stages
hypermetabolism occured preferentially in the CA1 subregion of
the hippocampus in the absence of structural differences. As
patients progressed to syndromal psychosis, hypermetabolism
spread from CA1 to the subiculum and, importantly, hippocam-
pal volume reduction became evident. A precise spatial con-
cordance was observed between the anatomical pattern of
hypermetabolism and atrophy, occurring in the left CA1 and
subiculum in the anterior hippocampal body.
This anatomical concordance suggested a common upstream
mechanism, so informed by previous studies we used the
NMDA antagonist model of psychosis to test the hypothesis
that an elevation in glutamate acts a pathogenic driver. Acute
systemic administration of NMDA antagonists such as ketamine
and phencyclidine recapitulates many of the features of schizo-
phrenia in humans, and in experimental animals elevates extra-
cellular glutamate at doses that produce schizophrenia-relevant
changes in behavior (Krystal et al., 1994; Moghaddam and Javitt,
2012). Moreover, chronic or repeated exposure to NMDA
antagonists produces schizophrenia-relevant cognitive deficits
(Jentsch and Roth, 1999) and is associated with cortical gray
matter loss in humans (Liao et al., 2011). Previous studies, how-
ever, have not mapped ketamine’s effect on glutamate levels
within the hippocampal circuit. Here, acute ketamine administra-
tion produced an anatomical gradient of hippocampal hyperme-
tabolism comparable to that observed in the psychosis stage of
schizophrenia. Moreover, chronic administration of ketamine for
1 month caused a shift in the basal state of the hippocampus
to hypermetabolism, atrophy, and downregulation of PV+ inter-88 Neuron 78, 81–93, April 10, 2013 ª2013 Elsevier Inc.neurons, all of which match the anatomical pattern of hippocam-
pal dysfunction observed in patients.
We tested the hypothesis that increases in extracellular gluta-
mate are required to produce these neuroimaging phenotypes in
three experiments in the rodent model: First, we found that keta-
mine-evoked increases in extracellular glutamate mirrored the
evoked fMRI pattern, with preferential changes found in the
CA1 subfield and subiculum subregion. Second, we established
a mechanistic link by showing that pre-treatment with a gluta-
mate mGluR 2/3 agonist known to inhibit glutamate release
blocked the ability of ketamine to evoke excess extracellular
glutamate and increases in CBV. Third, when studied longitudi-
nally, cotreatment with the glutamate release-limiting drug
protected against the effects of repeated ketamine on the PV+
interneurons and prevented the associated shift to basal hyper-
metabolism and hippocampal atrophy. Notably CA1 and subic-
ular subfields in the hippocampal body were most affected
with an overall anatomical pattern homologous with that found
for progression to psychosis in the human study.
The mGluR 2/3 agonist was an optimal choice to provide this
mechanistic link because of its selectivity in limiting glutamate
efflux, and its ability to block the behavioral and cognitive abnor-
malities produced by psychotomimetic drugs (Cartmell et al.,
1999; Imre et al., 2006; Krystal et al., 2005; Moghaddam and
Adams, 1998). A range of studies now support the hypothesis
that glutamate metabolism and neurotransmission play a critical
role in driving the cognitive and behavioral disturbances of
psychosis (Moghaddam and Javitt, 2012). In the context of sys-
temic NMDA receptor hypofunction, the condition modeled
here, NMDA receptor blockade has been shown in neocortex
Figure 7. The Effects of Extracellular Gluta-
mate on PV+ Interneuron Density in the
Repeated Ketamine Exposure Model
(A) Intermittent repeated ketamine exposure
resulted in a decrease in the apparent density
of PV+ interneurons in hippocampal CA sub-
fields; this effect is attenuated by LY379268
cotreatment. **p < 0.01 saline/ketamine group
versus saline control. Data are represented as
mean ± SEM.
(B) Decreases in PV+ expression (relative the
mean of the saline control group) are associated
at trend level with increases in basal rCBV
measured after one month of repeated treatment
with saline only (open symbols), ketamine with
saline cotreatment (red symbols), or ketamine with
LY379268 cotreatment (blue symbols) (r = .049,
p = 0.06).
(C) Across the same treatment groups there is
a negative association between posttreatment
basal rCBV measured after drug wash-out and
the change in hippocampal volumes across the
1 month treatment period (r = 0.57, p = 0.006).
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Javitt, 2012), thereby increasing metabolic demand and blood
flow (Rothman et al., 2002; Pellerin and Magistretti, 1994). A
similar cascade is likely to operate in the hippocampus. Differen-
tial regional vulnerability of NMDA receptor blockade may be
mediated at a molecular level by the relatively high density of
NMDA and AMPA receptors in CA1 relative to other hippocam-
pal subregions (Coultrap et al., 2005). AMPA receptors in partic-
ular may play an important role in the consequent synaptic and
hemodynamic state (Moghaddam et al., 1997).
The effect of repeated ketamine on PV+ GABAergic interneu-
rons observed here is consistent with previous studies showing
that NMDA antagonists lead to metabolic stress, morphologic
changes, and downregulation of PV expression in cortical neu-
rons (Behrens et al., 2007; c.f. Benneyworth et al., 2011; Keilhoff
et al., 2004; Vutskits et al., 2007). Further research is needed to
relate our results to postmortem findings in schizophrenia, which
have shown abnormalities in hippocampal GABAergic interneu-
rons (Heckers and Konradi, 2010), as well as defects in AMPA-
kainate and NMDA receptors (Gao et al., 2000; Harrison, 2004;
Law and Deakin, 2001). Our present findings do not speak to
the relevance of NMDA receptors on GABAergic interneurons
for a hyperglutamatergic state in schizophrenia (see models in
Greene, 2001; Lisman et al., 2008; Moghaddam and Javitt,
2012). They do, however, support a model perhaps more rele-
vant to the pathogenesis of psychosis: repeated hyperglutama-
tergic events leading over time to a sustained loss of function in
the interneurons and hippocampal disinhibition.
The current study supports the hypothesis that downregula-
tion of hippocampal interneurons may have significant feed-
forward excitation of the hippocampal trisynaptic circuit as
originally hypothesized by Benes (1999). Subsequent elevations
in extracellular glutamate may drive further hypermetabolism,
progressive interneuronal pathology, and eventual atrophy inthe CA1 and subiculum. Consistent with this hypothesis, recent
in vivo studies using magnetic resonance spectroscopy (MRS)
suggest that elevations in glutamate might be characteristic
of incipient psychosis in schizophrenia and associated with
emergent psychotic symptoms in healthy comparison subjects
receiving acute ketamine challenge (de la Fuente-Sandoval
et al., 2011; Stone et al., 2012). Currently, however, MRS does
not possess sufficient spatial resolution to measure glutamate
in individual hippocampal subregions.
In addition to clarifying mechanisms of disease, the results of
our study have several clinical implications. CA1 hypermetabo-
lism may be a possible state-specific biomarker of prodromal
and early psychotic disorders. As with other progressive disor-
ders of the brain, such as Alzheimer’s disease, early detection
during prodromal stages, when the disease is restricted to rela-
tively confined areas of the brain, has emerged as an important
goal for improving therapeutic efficacy. By showing that hyper-
metabolism occurs before atrophy, our results reinforce this
concept, because reversing functional defects are likely easier
before the loss of brain tissue. Moreover, our results demon-
strate that regulating excess extracellular glutamate and
reducing abnormal hippocampal hypermetabolism is protective
of hippocampal volume, one of the first and foremost regions to
show volumetric loss in schizophrenia (Steen et al., 2006).
Because the glutamate-driven metabolic and structural
imaging phenotypes identified in the current study are associ-
ated with the emergence of psychosis, we hypothesize that
regulating glutamate may be particularly effective during early
stages of schizophrenia, a factor not yet considered in recent
clinical trials. Notably, glutamate-reducing agents include
approved drugs such as lamotrigine or gabapentin, as well as
the experimental compound LY404309. It is possible, therefore,
to design a study in subjects at clinical high risk for psychotic dis-
orders to test whether glutamate-regulating drugs can normalizeNeuron 78, 81–93, April 10, 2013 ª2013 Elsevier Inc. 89
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and prevent progression to threshold psychotic disorder from
prodromal stages of disease.
EXPERIMENTAL PROCEDURES
Human Studies
Subjects and Clinical Assessment
Eligibility for study participation and prodromal symptom severity were ascer-
tained using the structured interview for prodromal syndromes and scale of
prodromal symptoms (SIPS/SOPS) (Miller et al., 2003) as previously described
(Schobel et al., 2009b). Participants were assessed quarterly for conversion to
psychosis using theSOPS, and its presence of psychosis (POPS) criteria (Miller
et al., 2003). All aspects of the study including clinical assessment and imaging
protocols were approved throughColumbia University’s IRB and the NewYork
State Psychiatric Institute. Written informed consent for subjects over age 18
years or written child assent with written parental consent for subjects under
18 years was obtained after complete description of the study procedures.
Hippocampal Cerebral Blood Volume
As previously reviewed, the use of the contrast agent gadolinium to map cere-
bral blood volume (CBV) with MRI is a basal state functional imaging approach
that provides high spatial resolution (Lin et al., 1999). Cerebral blood volume
maps were generated according to methodology as previously described on
a Philips 1.5 T scanner (Moreno et al., 2007). Postgadolinium enhanced images
were aligned to pregadolinium images in SPM5. Subtracted images (post
minus pre) were then divided by the contrast-induced difference in signal
measured from the superior sagittal sinus (average value of sagittal sinus
used in calculation). An investigator blind to subject grouping performed all
imaging processing. Of note, all eighteen of the original clinical high-risk par-
ticipants that were a part of the baseline sample described in Schobel et al.
(2009b) were included in the present manuscript, with n = 7 additional cases
ascertained at baseline and follow-up, to bring the study to a total n = 25 base-
line cases and n = 20 completing the longitudinal follow-up. All imaging cases
were reanalyzed by a single blinded rater for the present manuscript. Strict
anatomic criteria for hippocampal subregions along the hippocampal long
axis were used to identify brain subregions as previously described (Schobel
et al., 2009b).
Hippocampal Structure and Morphometry:
Hippocampal volumes were segmented from the precontrast T1 weighted
images as previously described using ITK-SNAP (Schobel et al., 2009a; Yush-
kevich et al., 2006). After validation, these segmented volumes were prepro-
cessed and smoothed (Morey et al., 2009). Point-basedmodels were obtained
via spherical parameterizations and subsequent SPHARM-PDM representa-
tion. For more detail of the 3D hippocampal shape representation, please refer
to (Styner et al., 2003, 2007). Statistical analysis was carried out on the afore-
mentioned point-based models as described below.
Statistical Analysis
The statistical models used to analyze the data for clinical studies are found in
Supplemental Experimental Procedures.
Rodent Studies
Subjects
A total of 88 C57/BL6 (Taconic Biosciences) male mice aged 50–70 days were
used for the acute ketamine experiment. For the longitudinal study, we used 42
C57/BL6 mice (Taconic) that were aged 35-45 days at the beginning of treat-
ment and imaged and processed for histology at 65–75 days. All animals were
housed 5 to a cage in a vivarium maintained on a 12 hr light/dark cycle. Exper-
iments took place during the light portion of the cycle, and food andwater were
available ad libitum. All procedures were approved by the Columbia University
and New York State Psychiatric Institute Institutional Animal Care and Use
Committees.
Drug Study Design
Ketamine (VedCo; 100mg/kg concentration) was diluted to 0.8–3.2 mg/ml and
injected at a volume of 10 ml/kg body weight. It was chosen on the basis of its
psychotomimetic properties and wider use in (and thus translatability to)
humans than other NMDA antagonists. LY379268 (Tocris) was chosen on90 Neuron 78, 81–93, April 10, 2013 ª2013 Elsevier Inc.the basis of its function as an agonist at presynaptic glutamate metabotropic
2/3 receptors and ability to inhibit synaptic glutamate release (Lorrain et al.,
2003; Moghaddam and Javitt, 2012; Monn et al., 1999). For acute experi-
ments, ketamine (30 mg/kg) or saline challenge was administered after
baseline measurement of CBV or extracellular glutamate. For acute drug
pretreatment studies, LY379268 (10 mg/kg) versus saline was administered
intraperitoneally (i.p.) once per day for 5 days prior to measurement of hippo-
campal CBV or extracellular glutamate. For longitudinal study of intermittent
repeated ketamine exposure, mice were treated 3 times per week with saline
(10 ml/kg, s.c.) or ketamine (8, 16, or 32 mg/kg, s.c.). For the drug cotreatment
longitudinal experiment, animals were administered LY379268 (10mg/kg, s.c.)
30 min prior to each ketamine treatment (16 mg/kg, s.c) 3 times per week for
1 month. Following the month of treatment, mice were imaged in the drug-free
condition after a 48 hr drug washout period.
Hippocampal Cerebral Blood Volume
High-resolution rodent CBV maps (86 mm) were generated as previously
described (Moreno et al., 2006, 2007). After baseline CBV values were estab-
lished, mice received either saline or ketamine as described above and three
16 min postchallenge image sequences were obtained.
Hippocampal Structure and Morphometry
MRI volumes of C57B6male mice from each group were quantified at baseline
(ages 35–45 days, n = 6–10 per group) and at follow-up (ages 65–75 days) for
total forebrain and total hippocampal volume using structural T-2 weighted
horizontal MRI images (24 slices, rostral to dorsal, 86 mM in plane resolution,
500 mMslice thickness). Volumeswere calculated by using a region-of-interest
technique from dorsal to rostral at the first appearance of cortex and hippo-
campus, respectively, following the external boundary of mouse cortical
mantle and hippocampus proper excluding entorhinal cortex (Figure 4C).
Rodent morphometry was conducted within a voxel-based framework as
described in Sawiak et al. (2009). Briefly, a unified segmentation approach
was implemented in SPM5 (Wellcome Department of Clinical Neurology,
London; http://www.fil.ion.ucl.ac.uk). Affine registered images were trans-
formed to atlas space and assigned a gray matter (GM) probability distribution
modulated by the Jacobian determinant of the transformation. Manually
segmented hippocampal ROIs were used to conduct small volume correction
in statistical analyses. Statistical analysis was performed in a factorial frame-
work implemented in SPM5, with treatment group as the between subject
factor and time as within subject factor. Small-volume correction was applied
using the hippocampal ROI generated above. Family-wise error (FEW) multi-
ple-comparison correction was applied to all statistical tests with a corrected
height threshold of p = 0.05. Surface renderings of whole-brain and hippocam-
pus ROIs were generated in 3D Slicer (www.slicer.org) using a volume ray
casting rendering equation. Maximum intensity projections of T- and F- statis-
tic maps were rendered and overlaid onto the ROI isosurfaces using the
volume render module in 3D Slicer.
Measurement of Extracellular Glutamate
The glutamate biosensor (model 7004, Pinnacle Technologies) was estab-
lished to be sensitive to micromolar concentrations of glutamate, able to
detect rapid changes in extracellular glutamate efflux (<0.5 s response),
selective for glutamate, and sufficiently small (130 mM dimension sensing
probe) to selectively measure changes within hippocampal subregions (see
Hu et al., 1994). On the morning of the experiment, glutamate biosensors
were calibrated against glutamic acid using a three-step concentration curve
applied over 3 min. The selectivity of the biosensor response was then tested
by administration of 125 mM of ascorbic acid and tracing observed over an
additional 3 min. After precalibration, the biosensors were rinsed in ultra-
pure H2O and then immediately implanted via the arm of the stereotax for
in vivo recording. Sensitivity of the biosensor response (at least 3 nA per
10 mM glutamic acid), stability of the response, as well as a nonresponse to
ascorbic acid were required for the biosensor to be inserted for in vivo
experiments.
Mice were anesthetized with chloral hydrate (400 mg/kg) and placed in a
stereotax with heating pad postinduction, at which time a 0.6 mm i.p. catheter
for drug delivery was inserted. Calibrated biosensors were then directly
inserted into the ventral hippocampus and connected to the potentiostat for
in vivo recording. Following baseline stabilization of extracellular glutamate
signal over one hour, ketamine 30mg/kg or saline was administered via the
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campal subregion location over the following 30 min (Bregma coordinates EC
A-P 4.7, M-L 3.0, D-V 4.0; dentate gyrus A-P 3.4, M-L 2.7, D-V 3.8; CA1 sub-
field A-P 3.5, M-L 3.25, D-V 4.2; subiculum A-P 3.9, M-L 3.25, D-V 4.2.) Post-
experiment, animals were removed from the stereotax, overdosed with chloral
hydrate and euthanized by cervical dislocation. Brains were postfixed in para-
formaldehyde (4%), cryoprotected, cryosectioned, thaw mounted, dried,
stained with a mixture of cresyl violet and neutral red, dehydrated/defatted,
and coverslipped. Probe placements were verified according to the atlas of
(Paxinos and Franklin, 2001; Figure S2).
Histology and Estimation of PV+ Cell Counts and Hippocampal
Cross-Sectional Area
In a subset of the mice used for the longitudinal study, brains were fixed via
transcardial perfusion of buffered saline followed by buffered 4% paraformal-
dehyde. The brains were then sectioned with a vibratome or cryoprotected
and cryosectioned. Coronal 40 micron-thick sections through hippocampus,
from the anterior pole to through the posterior extent of the CA fields (approx-
imately 4.3 mm posterior to Bregma). The starting point for sectioning was
randomly determined then sections were collected systematically (section
interval of either 3 or 4). For some brains post-fixed for more than a few
weeks, antigen was retrieved by heating in a 10 mM citrate buffer (pH 8.5,
temperature 80C). Parvalbumin was revealed with standard immunohisto-
chemical methods using a monoclonal anti-parvalbumin antibody (PV 235
mouse IgG1, Swant; dilution 1:800) and a rhodamine anti-mouse secondary
(Abcam; dilution 1:200). Following mounting and drying, sections were cover-
slipped with an antifading medium.
To control for variations in the quality of histology and section preservation,
modified stereologically based methods were used to determine PV+ cell den-
sity and average cross-sectional area of the body of the hippocampus. PV+
cells were identified by their relatively large soma lying with strata subpyrami-
dale, pyramidale, and oriens and the ‘‘baskets’’ frequently formed by their pro-
cesses around pyramidal cell soma. In sections between 1.0 and 4.0 posterior
to Bregma, PV+ cell density was quantified using combined optical fractionator
and Cavaleri estimation methods. To estimate changes in hippocampal size
following repeated drug treatment, cross-sectional area was calculated using
the Cavaleri estimation method for each section used for PV+ cell quantifica-
tion. For each brain, these sections were aligned according to Paxinos and
Franklin (2001) and the average cross-section area for the rostrodorsal body
(1.0 to 2.4 posterior to Bregma) and caudoventral body (2.5 to 4.0 mm poste-
rior to Bregma) of the hippocampus were calculated for each brain.
Statistical Analyses
The statistical models used to analyze the data for rodent studies are found in
Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.neuron.2013.02.011.
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